Cincinnati, OH – According to filings with the U.S. Securities and Exchange Commission, CinCor Pharma is raising $142,864,996.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Marc Degaridel played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About CinCor Pharma
CinCor is a clinical stage cardiorenal therapeutics company with a novel clinical-stage candidate, CIN-107, that we believe has the potential to dramatically expand therapeutic options for patients suffering from hypertension and its associated risks. CIN-107 also has the potential to treat other diseases where aldosterone plays a significant role in their pathogenesis. Despite decades of understanding the importance of controlling hypertension and the availability of multiple approved therapies, a significant number of US adults have uncontrolled blood pressure listed as a primary or secondary cause of death each year. We view the evidence for the benefits of reducing blood pressure as overwhelming and is supported by the medical communitys recommendations to drive blood pressure to even lower levels. Yet the current standard of care has evolved very little over recent decades while millions of people fail to reach targeted blood pressure levels. We believe we can change this with CIN-107. CIN-107 is a highly selective aldosterone synthase inhibitor, which impedes the enzyme responsible for the synthesis of aldosterone in the adrenal gland. Aldosterone is part of the renin angiotensin-aldosterone system (RAAS) with a primary function to regulate both electrolyte and volume balance.

To learn more about CinCor Pharma, visit http://cincor.com/

Contact:
Marc Degaridel, Chief Executive Officer
844-531-1834
mdegaridel@cincor.com
https://www.linkedin.com/in/marc-de-garidel-097982/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved